New study examines stigma toward women who lose weight using GLP-1 medications

Friday, April 17, 2026 – Saturday, April 18 - In a new study exploring stigma associated with the use of GLP-1 drugs for weight loss, women who lost weight using GLP-1 medications were judged more harshly than those who lost weight through diet and exercise, with negative reactions driven largely by beliefs that medication-assisted weight loss is a "shortcut." The study also found higher levels of stigma when the women in sample scenarios were portrayed as white rather than Black.

Lilly’s GLP-1 Foundayo aces MACE in DILI of a phase III

Thursday, April 16, 2026 – Friday, April 17 - Wall Street met with satisfaction but not surprise Eli Lilly and Co.’s undeniably positive top-line results from the phase III Achieve-4 study testing the efficacy and safety of Foundayo (orforglipron) compared to insulin glargine in adults with type 2 diabetes and obesity or overweight at increased cardiovascular risk.